The clinical pharmacology of VM26 and VP16-213
- 1 April 1982
- journal article
- review article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 7 (2-3) , 133-140
- https://doi.org/10.1007/bf00254535
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Analysis of the anticancer drugs VP 16-213 and VM 26 and their metabolites by high-performance liquid chromatographyJournal of Chromatography B: Biomedical Sciences and Applications, 1980
- Podophyllotoxin derivative VP 16-213Cancer Chemotherapy and Pharmacology, 1979
- Etoposide (VP-16-213)Cancer Treatment Reviews, 1979
- VP-16-213 MONOTHERAPY FOR REMISSION INDUCTION OF SMALL CELL LUNG-CANCER - RANDOMIZED TRIAL USING 3 DOSAGE SCHEDULES1978
- The Role of Drug Disposition Kinetics on Cellular Transport of the Antineoplastic Agent VM-26Drug Metabolism Reviews, 1978
- VM 26 and VP 16–213: A comparative analysisCancer, 1977
- PHASE I CLINICAL-TRIAL OF AN ORAL SOLUTION OF VP-16-2131976
- Comparison of the human pharmacokinetics of VM-26 and VP-16, two antineoplastic epipodophyllotoxin glucopyranoside derivativesPublished by Elsevier ,1975
- PTG, a new antineoplastic epipodophyllotoxinClinical Pharmacology & Therapeutics, 1975
- Phase I clinical trial of a new antitumor agent, 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene- -D-glucopyranoside) (NSC-141540; VP-16-213).1972